Notice: Trying to get property 'slug' of non-object in /home/sgumdev/public_html/wp-content/themes/sgum_2016/single.php on line 44

written by reader Cabot’s 5 Top Stocks to buy in 2016

By hearring, March 29, 2016

Any insight on the the stocks Cabot’s touting.
Ligand Pharmaceuticals (LGND)
Solar Edge (SEDG)
Universal Display

Thank you…Karen

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments

Notice: Undefined variable: karmaOutput in /home/sgumdev/public_html/wp-content/themes/sgum_2016/functions.php on line 3288

Notice: Undefined variable: karmaOutput in /home/sgumdev/public_html/wp-content/themes/sgum_2016/functions.php on line 3288
6 years ago

$LGND-Karen, this is probably the best and most recent article by Travis on Ligand Pharmaceuticals:

👍 11466
6 years ago

$LGND also covered in this February article: Best2You-Ben

Add a Topic
👍 11466
Travis Johnson, Stock Gumshoe

I haven’t looked at Universal Display lately, or Solar Edge at all, but do, as sogiam notes, own Ligand and find it an appealing but fairly high risk holding. Not as risky as junior biotechs awaiting trial results, but riskier than the “royalties” idea might convey because they are extremely reliant on two royalties (Kyprolis and Promacta) for the lion’s share of income. There is potential for high reward as well, of course, and that depends on some of their other top half-dozen drugs in development getting approved and selling well enough to generate substantial royalties… and their cost base is very low, since they don’t do much of the science or development work.

Add a Topic
👍 15112

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info